Authors: Roddy S. O’Connor
Published: 2023-12-06
DOI: 10.1126/sciadv.adm6816
Source: Full article
Inhibiting a key metabolic enzyme, ACLY, in cancer cells impacts T cell function in immunotherapy-resistant tumors and may offer a target for therapeutic treatment.